Bessemer Group Inc Bei Gene, Ltd. Transaction History

Bessemer Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$121.11 - $216.05 $4,359 - $7,777	-36 Closed	0 $0
Q4 2021 Jan 27, 2022	SELL	$248.56 - $389.34 $2,237 - $3,504	-9 Reduced 20.0%	36 $10,000
Q3 2021 Nov 12, 2021	BUY	$249.6 - $403.14 $748 - $1,209	3 Added 7.14%	45 $16,000
Q2 2021 Aug 06, 2021	SELL	$292.75 - $367.01 $26,933 - $33,764	-92 Reduced 68.66%	42 $14,000
Q1 2021 May 13, 2021	SELL	$260.64 - $382.12 $6.57 Million - $9.63 Million	-25,214 Reduced 99.47%	134 $46,000
Q4 2020 Feb 09, 2021	SELL	$221.31 - $316.61 $3.09 Million - $4.42 Million	-13,947 Reduced 35.49%	25,348 $6.55 Million
Q3 2020 Nov 12, 2020	BUY	$189.18 - $286.44 $7.43 Million - $11.3 Million	39,295 New	39,295 $11.3 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

Stay updated on Bessemer Group Inc with notifications on news.